Thyroid Remnant Radioiodine Ablation with Recombinant Human Thyrotropin

[1]  A. Pinchera,et al.  Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. , 2002, The Journal of clinical endocrinology and metabolism.

[2]  J. Robbins.  Pharmacology of bovine and human thyrotropin: an historical perspective. , 1999, Thyroid : official journal of the American Thyroid Association.

[3]  J. Meek,et al.  Mechanism of allergy to components of commercial bovine thyrotropin. , 1973, The Journal of allergy and clinical immunology.

[4]  S. Larson,et al.  A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  G. T. Krishnamurthy,et al.  Neutralizing antibodies to bovine thyrotropin in immunized patients with thyroid cancer. , 1980, The Journal of clinical endocrinology and metabolism.

[6]  P. Perros.  Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. , 1999, Journal of endocrinological investigation.

[7]  R. Robbins,et al.  Recombinant Human Thyrotropin and Thyroid Cancer Management , 2003 .

[8]  R. Kloos,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .

[9]  M. Luster,et al.  Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. , 2006, European journal of endocrinology.

[10]  S. Larson,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. , 2001, Thyroid : official journal of the American Thyroid Association.

[11]  R. Wahl,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[12]  Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. , 2000, The Journal of clinical endocrinology and metabolism.

[13]  M. Sonenberg,et al.  An 18 Year Study of the Use of Beef Thyrotropin to Increase I131 Uptake in Metastatic Thyroid Cancer , 1964 .

[14]  T. Pilli,et al.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.

[15]  G. Mariani,et al.  Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. , 2003, The Journal of clinical endocrinology and metabolism.

[16]  G. Lindstedt,et al.  Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone , 2002, Journal of endocrinological investigation.

[17]  B. Haugen,et al.  A review of the potential uses for recombinant human TSH in patients with thyroid cancer and nodular goiter , 2004, Clinical endocrinology.

[18]  S. M. Seidlin,et al.  Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma; a preliminary report. , 1948, The Journal of clinical endocrinology and metabolism.